☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
pulmonary arterial hypertension
United Therapeutics Presents Results of Tyvaso DPI in BREEZE Clinical Study for the Treatment of Pulmonary Arterial Hypertension a...
September 8, 2021
Janssen Reports Post-Hoc Analysis of P-III GRIPHON and P-IIIb TRITON Studies of Uptravi (selexipag) for the Treatment of Pulmonary...
August 31, 2021
Janssen's Uptravi (selexipag) Receives the US FDA's Approval for IV Use in Adults with Pulmonary Arterial Hypertension
August 2, 2021
Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension
April 22, 2021
Acceleron Presents Results of Sotatercept in P-II PULSAR Trial for the Treatment of Pulmonary Arterial Hypertension- Published in...
April 2, 2021
Janssen Reports the NDA Submission to the US FDA for Uptravi (selexipag- IV) to Treat Pulmonary Arterial Hypertension
October 1, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.